Avadel Pharmaceuticals ADR Logo
US05337M1045
A2DJR8
AVDL

Avadel Pharmaceuticals ADR

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 18,50 € (+1,48%). La mediana è 17,26 € (-5,32%).

Acquista
  8
Mantieni
  6
Vendi
  0

  • TIG Advisors reports 4.18% stake in Avadel Pharmaceuticals

    TIG Advisors disclosed a 4.18% stake in Avadel Pharmaceuticals, holding 4,102,946 common shares. On January 15 the firm acquired 251,499 shares at prices between $21.50 and $21.53 per share. The filing states that TIG Advisors holds no short positions or Avadel‑related derivatives; no tender offer was indicated. » Altro su de.investing.com


  • Avadel Pharmaceuticals: Morgan Stanley reports purchase and sale of 327 shares

    Morgan Stanley & Co. International plc stated in a mandatory notification to the Irish Takeover Panel that on 14 January 2026 it, as an exempt principal trader, acquired and subsequently disposed of 327 ordinary shares of Avadel Pharmaceuticals. The transactions took place at prices between $21.4931 and $21.5440 per share. The disclosure notes a connection between Morgan Stanley and Avadel Pharmaceuticals; no additional derivative transactions or options were reported. The filing was made under Rule 38 of the Irish Takeover Rules to ensure transparency in potential takeover situations. » Altro su de.investing.com


  • FIL reports 3.14% stake in Avadel Pharmaceuticals

    FIL and its subsidiaries hold a total of 3,063,023 ordinary shares of Avadel Pharmaceuticals as of the record date January 13, 2026, representing a 3.14% stake. The mandatory notification also cites a recent transaction to purchase 80,000 ordinary shares at USD 21.50 each. There are no agreements or option arrangements between the reporting parties and other companies; the holding was disclosed under Rule 8.3 of the Irish Takeover Panel. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Avadel Pharmaceuticals ADR ha registrato ricavi pari a 66,01 Mln € e un utile netto di 17,04K €
(EUR) set 2025
YoY
Ricavi 66,01 Mln -
Utile lordo 68,57 Mln -
Utile netto 17,04K -
EBITDA 3,05 Mln -

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
1,83 Mld €
Numero di azioni
98,15 Mln
Massimo/minimo a 52 settimane
20,34 € - 5,51 €
Dividendi No
Beta
1,31
Rapporto P/E
431,08
Rapporto PEG
0,66
Rapporto P/B
21,39
Rapporto P/S
10,72

Profilo aziendale

Avadel Pharmaceuticals plc ist als biopharmazeutisches Unternehmen in den Vereinigten Staaten tätig. Sein führender Produktkandidat ist FT218, eine Formulierung von Natriumoxybat, die sich in einer klinischen Phase-3-Studie zur Behandlung von exzessiver Tagesschläfrigkeit und Kataplexie bei Erwachsenen mit Narkolepsie befindet. Das Unternehmen war früher unter dem Namen Flamel Technologies SA bekannt und änderte im Januar 2017 seinen Namen in Avadel Pharmaceuticals plc. Avadel Pharmaceuticals plc wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Dublin, Irland.

Nome
Avadel Pharmaceuticals ADR
CEO
Gregory J. Divis Jr.
Sede centrale Dublin,
Stati Uniti
Sito web
Settore
Materiali
Industria
Prodotti chimici
Quotazione in borsa
07/06/1996
Dipendenti 188

Simboli di borsa

Borsa Simbolo
NASDAQ
AVDL
🍪

Parqet  usa i cookie. Scopri di più